counta1797
Medical Applications: Zimmer Biomet to Acquire Embody, Inc.
ASME Membership

Additive Manufacturing (AM)

AM showcases the latest technology and industry developments with in-depth case studies, resources, interviews with experts and events.

    Zimmer Biomet to Acquire Embody, Inc.

    Zimmer Biomet has reached agreement to acquire Embody. Both are in medical applications of 3D printing/additive manufacturing.

    WARSAW, Ind./Jan. 5, 2023 — Zimmer Biomet Holdings, Inc. announced that it has reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing and up to an additional $120 million subject to achieving future regulatory and commercial milestones over a three year period. The acquisition is expected to be accretive to overall revenue growth and slightly dilutive to adjusted earnings per share in 2023. Both companies have been leaders in the use of additive manufacturing (3D printing) technologies for medical applications.

    The acquisition includes Embody’s complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY® biointegrative implant for tendon healing and TAPESTRY® RC, one of the first arthroscopic implant systems for rotator cuff repair.

    “Embody’s differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons,” said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. “The planned acquisition of Embody is an important step in the ongoing transformation of ZB and the execution of our strategic priority to increase long-term growth and drive value creation.”

    “We are excited for the potential to create value for patients and customers in new ways and believe the combination of Embody’s innovative products and Zimmer Biomet’s established portfolio will bring new solutions to the market that could redefine the standard of care,” said Jeff Conroy, Chief Executive Officer of Embody.

    The transaction is subject to customary closing conditions and is expected to be completed in February 2023.

    Guggenheim Securities is acting as financial advisor to Embody.

    related /

  • 2022 trends and opportunities for additive manufacturing indicate exciting times ahead. National efforts are supporting developments and expansion. National Efforts Expand Existing Additive Manufacturing Trends and Opportunities
  • As 2023 begins, the community continues to accelerate with announcements of production additive manufacturing applications. Additive Manufacturing Applications & Acceleration: AM News Roundup for December 19, 2022 – January 6, 2023
  • AMUG 2023 Reviewed AMUG 2023 Takeaways